Switch theme
Sign up to access all valuation multiples
Raia Drogasil SA is a large retail drug store operator in Brazil. The company is engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. Its brands include Impulso, Amplimed, HealthBit, Stix, 4Bio, Drogasil, Raia and others.
2011
53.4K+
LTM Revenue $7.5B
LTM EBITDA $596M
$5.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Droga Raia has a last 12-month revenue (LTM) of $7.5B and a last 12-month EBITDA of $596M.
In the most recent fiscal year, Droga Raia achieved revenue of $6.8B and an EBITDA of $552M.
Droga Raia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Droga Raia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.5B | XXX | $6.8B | XXX | XXX | XXX |
| Gross Profit | $2.5B | XXX | $2.0B | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $596M | XXX | $552M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $391M | XXX | $416M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $215M | XXX | $210M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $486M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Droga Raia's stock price is BRL 15 (or $3).
Droga Raia has current market cap of BRL 25.4B (or $4.5B), and EV of BRL 32.7B (or $5.7B).
See Droga Raia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.7B | $4.5B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Droga Raia has market cap of $4.5B and EV of $5.7B.
Droga Raia's trades at 0.8x EV/Revenue multiple, and 10.4x EV/EBITDA.
Equity research analysts estimate Droga Raia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Droga Raia has a P/E ratio of 20.8x.
See valuation multiples for Droga Raia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.5B | XXX | $4.5B | XXX | XXX | XXX |
| EV (current) | $5.7B | XXX | $5.7B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 9.6x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBIT | 14.7x | XXX | 13.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.8x | XXX | 21.2x | XXX | XXX | XXX |
| EV/FCF | 32.0x | XXX | 52.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDroga Raia's last 12 month revenue growth is 9%
Droga Raia's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $30K for the same period.
Droga Raia's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Droga Raia's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Droga Raia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $30K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Droga Raia acquired XXX companies to date.
Last acquisition by Droga Raia was XXXXXXXX, XXXXX XXXXX XXXXXX . Droga Raia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Droga Raia founded? | Droga Raia was founded in 2011. |
| Where is Droga Raia headquartered? | Droga Raia is headquartered in Brazil. |
| How many employees does Droga Raia have? | As of today, Droga Raia has 53.4K+ employees. |
| Is Droga Raia publicy listed? | Yes, Droga Raia is a public company listed on BVMF. |
| What is the stock symbol of Droga Raia? | Droga Raia trades under RADL3 ticker. |
| When did Droga Raia go public? | Droga Raia went public in 1995. |
| Who are competitors of Droga Raia? | Similar companies to Droga Raia include e.g. MedPlus India, SC Ropharma, Pague Menos, Redcare Pharmacy. |
| What is the current market cap of Droga Raia? | Droga Raia's current market cap is $4.5B |
| What is the current revenue of Droga Raia? | Droga Raia's last 12 months revenue is $7.5B. |
| What is the current revenue growth of Droga Raia? | Droga Raia revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Droga Raia? | Current revenue multiple of Droga Raia is 0.8x. |
| Is Droga Raia profitable? | Yes, Droga Raia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Droga Raia? | Droga Raia's last 12 months EBITDA is $596M. |
| What is Droga Raia's EBITDA margin? | Droga Raia's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Droga Raia? | Current EBITDA multiple of Droga Raia is 9.6x. |
| What is the current FCF of Droga Raia? | Droga Raia's last 12 months FCF is $180M. |
| What is Droga Raia's FCF margin? | Droga Raia's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Droga Raia? | Current FCF multiple of Droga Raia is 32.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
